Show simple item record

dc.contributor.authorHuang, Jinsha
dc.contributor.authorZhang, Zhentao
dc.contributor.authorZhang, Zhaowen
dc.contributor.authorLiu, Xingyuan
dc.contributor.authorJia, Min
dc.contributor.authorChen, Chunnuan
dc.contributor.authorCao, Xuebing
dc.contributor.authorLiang, Zhihou
dc.contributor.authorSun, Shenggang
dc.contributor.authorXiong, Nian
dc.contributor.authorXiong, Jing
dc.contributor.authorWang, Fang
dc.contributor.authorLin, Zhicheng
dc.contributor.authorWang, Tao
dc.date.accessioned2010-12-21T18:12:17Z
dc.date.issued2009
dc.identifier.citationXiong, Nian, Jinsha Huang, Zhentao Zhang, Zhaowen Zhang, Jing Xiong, Xingyuan Liu, Min Jia, et al. 2009. Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's Disease. PLoS ONE 4(11): e7878.en_US
dc.identifier.issn1932-6203en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4632588
dc.description.abstractA clinically-related animal model of Parkinson's disease (PD) may enable the elucidation of the etiology of the disease and assist the development of medications. However, none of the current neurotoxin-based models recapitulates the main clinical features of the disease or the pathological hallmarks, such as dopamine (DA) neuron specificity of degeneration and Lewy body formation, which limits the use of these models in PD research. To overcome these limitations, we developed a rat model by stereotaxically (ST) infusing small doses of the mitochondrial complex-I inhibitor, rotenone, into two brain sites: the right ventral tegmental area and the substantia nigra. Four weeks after ST rotenone administration, tyrosine hydroxylase (TH) immunoreactivity in the infusion side decreased by 43.7%, in contrast to a 75.8% decrease observed in rats treated systemically with rotenone (SYS). The rotenone infusion also reduced the DA content, the glutathione and superoxide dismutase activities, and induced alpha-synuclein expression, when compared to the contralateral side. This ST model displays neither peripheral toxicity or mortality and has a high success rate. This rotenone-based ST model thus recapitulates the slow and specific loss of DA neurons and better mimics the clinical features of idiopathic PD, representing a reliable and more clinically-related model for PD research.en_US
dc.language.isoen_USen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.isversionofdoi:10.1371/journal.pone.0007878en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774159/pdf/en_US
dash.licenseLAA
dc.subjectneurological disordersen_US
dc.subjectneuroscienceen_US
dc.subjectbehavioral neuroscienceen_US
dc.subjectmotor systemsen_US
dc.subjectneurology of disease and regenerationen_US
dc.subjectneuronal and glial cell biologyen_US
dc.subjectmovement disordersen_US
dc.subjectneuropharmacologyen_US
dc.titleStereotaxical Infusion of Rotenone: A Reliable Rodent Model for Parkinson's Diseaseen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalPLoS ONEen_US
dash.depositing.authorLin, Zhicheng
dc.date.available2010-12-21T18:12:17Z
dash.affiliation.otherHMS^Psychiatry-McLean Hospitalen_US
dc.identifier.doi10.1371/journal.pone.0007878*
dash.authorsorderedfalse
dash.contributor.affiliatedXiong, Nian
dash.contributor.affiliatedLin, Zhicheng


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record